New Biology Economy

New Biology Economy tracks news of the emerging molecular biology tools marketplace, which is building on foundational biotechnical advances to create new insights into complex biological systems. This blog begins with the understanding that traditional business methods must change to enable innovation to create wealth and eventually benefit patients. This will require cooperation, new ways of protecting intellectual property, and will spawn new types of business organizations.

Google
WWW New Biology Economy

Friday, August 19, 2005

Tennessee Funders Partner With Battelle; UK Genomics Services Provider Spins Out

  • A group of eastern Tennessee investors has organized with the goal of creating a $35 million venture capital fund, Innovation Valley Partners, targeting early-stage high technology companies nationally.

    Battelle Ventures, a $150 million fund based in Princeton, NJ, will manage the group's investments. Battelle Ventures is organized to commercialize technologies emerging from Battelle-managed national labs, such as Tennessee-based Oak Ridge National Laboratory, and others.

  • The managers of Cambridge, UK-based Geneservice have completed a buyout of the company from its parent, Medical Research Council, a government funded agency.

    The 25-employee company will operate as a genomic reagents and provider of services that include sequencing, genotyping, microarray expression analysis and whole genome amplification.

    The MRC spinout lists 900 active customers including many of the large academic institutes in the US and UK as well as pre-clinical R&D labs in the biotechnology sector.
    "We found that venture capitalists simply were not interested in us as a products and services company,” Tom Weaver, the company's CEO, told UK Business Weekly. “We have a viable commercial proposition in place – we have been breaking even for a number of years within the MRC – and we are now in a position to build a profitable business.”

    Financial details of the transaction were not disclosed.The deal was partially financed by Lloyds TSB Corporate Technology & Life Sciences team, Geneservice said.

  • Blogarama - The Blog Directory Business Blog Top Sites